Barclays lowered the firm’s price target on Editas Medicine (EDIT) to $5 from $7 and keeps an Equal Weight rating on the shares. The company’s Q3 was incremental following the strategic update, the analyst tells investors in a research note.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine Reports Q3 2024 Results and Developments
- Editas Medicine price target lowered to $5 from $8 at RBC Capital
- Raymond James downgrades Editas on extended development timelines
- Editas Medicine downgraded to Market Perform from Outperform at Raymond James
- Editas Medicine reports Q3 EPS (75c), consensus (75c)